rational design of NIR nanoparticle delivery for precision diagnosis and treatment system of pancreatic cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045448

Enrollment

Unknown

Registered

2021-04-15

Start date

2021-06-01

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductal adenocarcinoma

Interventions

Normal group:Nil

Tumor group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Pancreatic cancer patients diagnosed as ductal adenocarcinoma of the pancreas by primary biopsy, imaging, ascites cytology, and hihiopathology, with surgical indications and voluntary surgical treatment; 2. No gender limits; 3. Aged 8-12 years; 4. It is in the I-III phase of the TNM staging system; 5. With complete clinical data and with follow-up conditions.

Exclusion criteria

Exclusion criteria: Complicated with other malignant tumors.

Design outcomes

Primary

Measure	Time frame
none;	—

Countries

China

Contacts

Public ContactCheng Yingsheng

Shanghai Sixth People's Hospital

chengyingsheng@hotmail.com+86 18917683588

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026